Bellevue flags US healthcare innovation as driving fresh investment opportunities

Bellevue Group AG flagged patient-outcome innovation as a key driver of healthcare investment opportunities from recent US conference takeaways.

• Roivant’s mosliciguat progress in pulmonary hypertension could intensify competition for United Therapeutics and Liquidia, broadening treatment choice.
• Roivant’s LISRAYA launch adds a commercial leg to its investment case, shifting focus from pipeline-only to revenue execution.
• Oral IL-23 therapy Icotrokinra from J&J and Protagonist showed strong uptake; combo regimens in inflammatory disease gained momentum.
• Medtronic’s turnaround narrative strengthened; Becton Dickinson’s post-divestment profile points to about 5% growth, with total return trending toward 10%.